Merck, Starpharma expand partnership to develop antibody drug conjugates

DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i

Merck and Orna Therapeutics collaborate to advance Orna’s nextgen RNA technology

Collaboration supports multiple discovery efforts, including vaccines

Merck KGaA posts higher earnings, profits across business segments

Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million

Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

Merck opens microbiology application lab in Jigani, Bengaluru

Merck’s first microbiology application and training lab in India

Merck updates on Phase 3 Keynote-412 trial in advanced head and neck squamous cell carcinoma

Merck and Orion collaborate for the development and commercialization of ODM-208

Orion to receive an upfront payment of USD 290 million

Merck launches international platform to discuss ‘Next-Gen Labs’

Merck is organizing one of the biggest South APAC Virtual Conclave on ‘Next-Gen Labs’ on 20th July.

Merck KGaA doubles HPAPI production capacity in Wisconsin

This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area

Merck presents positive results from phase 1/2 study evaluating V116

V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019